Radiotherapy of oligometastatic pelvic node relapses in patients with prostate cancer
Copyright © 2017 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved..
The Oligopelvis 2 studies is based on the assumption that salvage pelvic radiotherapy may prolong the interval between the first and the second intermittent hormone therapy sequence in pelvic lymph node oligometastatic prostate cancer. This phase 3 study will compare intermittent hormone therapy (standard arm) alone or combined with salvage pelvic radiotherapy (experimental arm).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique - 21(2017), 6-7 vom: 15. Okt., Seite 495-497 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Rechutes oligométastatiques ganglionnaires pelviennes au cours des cancers de la prostate : rôle de la prise en charge par radiothérapie |
|---|
| Beteiligte Personen: |
Supiot, S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.10.2017 Date Revised 05.10.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canrad.2017.07.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275200094 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275200094 | ||
| 003 | DE-627 | ||
| 005 | 20231225005138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.canrad.2017.07.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0917.xml |
| 035 | |a (DE-627)NLM275200094 | ||
| 035 | |a (NLM)28847462 | ||
| 035 | |a (PII)S1278-3218(17)30179-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Supiot, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiotherapy of oligometastatic pelvic node relapses in patients with prostate cancer |
| 246 | 3 | 3 | |a Rechutes oligométastatiques ganglionnaires pelviennes au cours des cancers de la prostate : rôle de la prise en charge par radiothérapie |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2017 | ||
| 500 | |a Date Revised 05.10.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved. | ||
| 520 | |a The Oligopelvis 2 studies is based on the assumption that salvage pelvic radiotherapy may prolong the interval between the first and the second intermittent hormone therapy sequence in pelvic lymph node oligometastatic prostate cancer. This phase 3 study will compare intermittent hormone therapy (standard arm) alone or combined with salvage pelvic radiotherapy (experimental arm) | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Androgen depriving therapy | |
| 650 | 4 | |a Cancer de prostate | |
| 650 | 4 | |a Hormonetherapy | |
| 650 | 4 | |a Hormonothérapie | |
| 650 | 4 | |a Irradiation | |
| 650 | 4 | |a Metastatic prostate cancer | |
| 650 | 4 | |a Métastase | |
| 650 | 4 | |a N1 | |
| 650 | 4 | |a Oligometastase | |
| 650 | 4 | |a Oligometastases | |
| 650 | 4 | |a Pelvis | |
| 650 | 4 | |a Prostate adenocarcinoma | |
| 650 | 4 | |a Suppression androgénique | |
| 650 | 4 | |a cN1 | |
| 650 | 4 | |a pN1 | |
| 700 | 1 | |a Doré, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rio, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique |d 1998 |g 21(2017), 6-7 vom: 15. Okt., Seite 495-497 |w (DE-627)NLM092193420 |x 1769-6658 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2017 |g number:6-7 |g day:15 |g month:10 |g pages:495-497 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canrad.2017.07.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2017 |e 6-7 |b 15 |c 10 |h 495-497 | ||